Less than three months after Spectrum Pharmaceuticals Inc. and Cell Therapeutics Inc. teamed up in a 50-50 joint venture to market the radioimmunotherapy drug Zevalin ([90Y]-ibritumomab tiuxetan), Spectrum is taking control of the compound. (BioWorld Today)

SAN DIEGO - After a rainy Monday, San Diego delivered a healthy dose of cloudless skies and warm sunshine during the American Heart Association's 2009 International Stroke Conference, held last week. (BioWorld Today)

A week after Phase III pirfenidone data in idiopathic pulmonary fibrosis sent its stock up 36 percent, InterMune Inc. decided to sell 3.5 million shares in a public offering. (BioWorld Today)